Transgene stock analysis
Transgene (0OCQ) Share Price & Analysis
0OCQ Stock Chart & Stats
- Day’s Range
- EUR 0.72 - EUR 0.72
- 52-Week Range
- EUR 0.68 - EUR 1.35
- Previous Close
- EUR 0.72
- Volume
- N/A
- Average Volume (3M)
- 1,076
- Market Cap
- EUR 198.97M
- Enterprise Value
- EUR 108.26M
- Total Cash (Recent Filing)
- EUR 92.84M
- Total Debt (Recent Filing)
- EUR 2.18M
- Price to Earnings (P/E)
- ―
- Beta
- 0.12
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage and a large equity base give Transgene more balance-sheet flexibility than its loss profile alone suggests. Limited debt reduces fixed financing pressure and can preserve room to fund clinical development, although continued losses still require careful capital management.
Oncology Pipeline
Transgene has a specialized oncology-immunotherapy focus supported by viral-vector and individualized vaccine approaches. A pipeline spanning multiple solid tumors and combination strategies creates several potential development paths, which can strengthen long-term strategic relevance if clinical programs progress.
Improved Cash Flow
Free cash flow improved about 49% versus 2024, indicating some movement in cash consumption even though it remained negative. If sustained, better cash discipline could extend funding runway and reduce the pace at which external capital is needed.
Bears Say
Persistent Losses
Persistent operating and net losses show that the current cost base is not supported by revenue, while the deeply negative 2025 margins provide no evidence of near-term profitability. This weak earnings foundation can constrain reinvestment and increase dependence on financing.
Revenue Collapse
The sharp 2025 revenue decline and highly volatile historical pattern make the top line an unreliable source of support for ongoing research and development spending. Without a sustainable revenue trajectory, future operating performance remains heavily dependent on successful pipeline progress.
Cash Burn And Funding Risk
Consistently negative operating and free cash flow means Transgene is consuming cash rather than funding development internally. Continued reliance on external capital can reduce financial flexibility and creates ongoing financing or dilution risk while losses persist.
Transgene News
0OCQ FAQ
What was Transgene’s price range in the past 12 months?
What is Transgene’s market cap?
When is Transgene’s upcoming earnings report date?
How were Transgene’s earnings last quarter?
Is Transgene overvalued?
Does Transgene pay dividends?
What is Transgene’s EPS estimate?
How many shares outstanding does Transgene have?
What happened to Transgene’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Transgene?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Transgene
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alessandro Riva
- Employees
- 152
- Website
- www.transgene.com
- Address
- 400, Boulevard Gonthier d’Andernach, Illkirch-Graffenstaden, GES, 67405, FR
Transgene (0OCQ) Earnings & Revenues
0OCQ Earnings Call
Earnings Call SentimentPositive
The call emphasized several strong positives: robust fundraising (EUR 105M), a strengthened balance sheet (EUR 39M debt conversion), compelling Phase I efficacy and durable immunogenicity signals for TG4050 (100% disease-free in treated Phase I patients; 73% immunogenicity with responses persisting 24 months), encouraging BT-001 combination data, and a clear plan for manufacturing and regulatory readiness. Counterbalancing these highlights are timing and operational risks (GMP readiness targeted Q3 2027), immature/pending pivotal readouts (Phase II 2-year DFS not yet available), ongoing cash burn (~EUR 38.2M in 2025) and some dependence on broader field validation. Overall, the positive clinical signals and strengthened financial position outweigh the execution and timing risks at this stage.
View all GB:0OCQ earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |









